Dr. Diane C. Bodurka, MD

Dr. Bodurka practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Bodurka's NPI, 1396834065, was assigned on October 12, 2006. Dr. Bodurka graduated from Georgetown University School Of Medicine in 1990. Dr. Bodurka's Texas license number on file is J6075.

Dr. Bodurka's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Bodurka's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service. Dr. Bodurka's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bodurka practices. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Bodurka's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Bodurka is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Bodurka's licenses on file in 4 states: Texas, Florida, Oklahoma and Alabama.

Dmand AI lists hysterectomy among the conditions Dr. Bodurka treats.

CMS data shows 209 Medicare services from Dr. Bodurka across 5 procedure codes in 2024, for 95 Medicare patients. Medicare paid $18,939 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 95 Medicare patients who saw Dr. Bodurka in 2024. The largest group is 65 to 74, with 53 patients. 72% of them have high blood pressure, and 62% have cancer. Their average risk score is 2.13, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bodurka's median patient age at 68, with 99% women.

In 2024, Dr. Bodurka wrote 115 Medicare Part D claims for 31 patients. 82% of them were for generic drugs. CMS names the drug for 48 of them, across 3 drugs with 11 or more claims each, at $784 in total drug cost. In 2023, CMS named 40 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Bodurka for performance year 2024, reported as part of a group. Dr. Bodurka accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bodurka as offering telehealth.

Dmand AI links 165 papers to Dr. Bodurka, published from 2004 to 2024. 2014 was the busiest year, with 11. The most frequent topics are Ovarian Neoplasms, Genital Neoplasms, Female and Antineoplastic Combined Chemotherapy Protocols. Dr. Bodurka has published most often in Gynecol Oncol. Dr. Bodurka's most frequent co-authors are Lois Michelle Ramondetta, MD, David M. Gershenson, MD and Charles F. Levenback, MD.

Dmand AI links Dr. Bodurka to 8 clinical trials. Conditions studied include Ovarian Neoplasms, Ovarian Diseases and Fallopian Tube Diseases. M.D. Anderson Cancer Center sponsors the most, 7.

CMS Open Payments shows 2 general payments to Dr. Bodurka from 1 drug or device company in 2016. Education make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $68.

Dmand AI lists 5 awards for Dr. Bodurka, most recently America's Top Doctors in 2014.

Dr. Bodurka graduated from Georgetown University School Of Medicine in 1990. Dr. Bodurka is a member of American College of Obstetricians and Gynecologists and ACS.

Dr. Bodurka is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. POS plans come from the most carriers, 4. Check the plan with the practice before a visit.